EMA assembles pharmaceutical developers to strengthen antimicrobial pipelines while, in the meantime, a study found the world’s rivers dangerously contaminated.
Scancell and Cancer Research UK use nanodelivery technology to activate the body’s immune system, boosting its ability to target and destroy cancer cells.
Enesi Pharma and OVG sign a collaborative agreement, hoping to combine a promising ingredient and an innovative delivery method to produce a plague vaccine.
The company’s Mavenclad treatment gains approval from the US FDA for the treatment of multiple sclerosis, eight years after it had been initially rejected.
Noramco partners with Nemus to produce an analogue of cannabidiol that possesses greater bioavailability, that could be used to treat diseases of the retina.
A pre-IND review by the US FDA has allowed Virpax to continue with NDAs for DSF100 and LBL100, two pain relief products with specialised drug delivery formulations.
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
